Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos

Babalola et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035 (date from preprint)
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Adjusted risk of viral+ at.. 64% Improvement Relative Risk ∆Spo2 (unadjusted) 41% Viral clearance 58% Viral clearance (b) 40% Time to viral- 49% primary Time to viral- (b) 34% Ivermectin  Babalola et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 60 patients in Nigeria (May - November 2020) Trial compares with lopinavir/ritonavir, results vs. placebo may differ Improved viral clearance (p=0.11) and recovery (p=0.073), not sig. c19ivm.org Babalola et al., QJM: An Int. J. Medic.., Jan 2021 Favorsivermectin Favorslopinavir/ri.. 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
Small RCT comparing ivermectin 6mg & 12mg q84hr with lopinavir/ritonavir, showing a statistically significant and dose dependent effect of ivermectin on reducing the time to PCR-.
The study does not report mortality, hospitalization, progression, recovery, etc. The paper does report change in SpO2 (Figure 3, ∆SpO2), where a similar improvement with a smaller p value is seen with ivermectin, however this result is unadjusted and there are large differences between groups. Specifically, baseline SpO2 is lower in the control group, giving the control group more room to improve, therefore the actual benefit of ivermectin is likely to be even larger than the benefit in ∆SpO2 shown.
See also1.
This is the 10th of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 29th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
adjusted risk of viral+ at day 5, 63.9% lower, RR 0.36, p = 0.11, treatment 40, control 20, adjusted per study, inverted to make RR<1 favor treatment.
relative ∆SpO2 (unadjusted), 41.5% better, RR 0.59, p = 0.07, treatment 38, control 18, figure 3.
risk of no viral clearance, 58.0% lower, HR 0.42, p = 0.01, treatment 20, control 20, inverted to make HR<1 favor treatment, 12mg - Cox proportional hazard model.
risk of no viral clearance, 40.5% lower, HR 0.60, p = 0.12, treatment 20, control 20, inverted to make HR<1 favor treatment, 6mg - Cox proportional hazard model.
time to viral-, 49.2% lower, relative time 0.51, p = 0.02, treatment 20, control 20, 12mg, primary outcome.
time to viral-, 34.4% lower, relative time 0.66, p = 0.08, treatment 20, control 20, 6mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Babalola et al., 6 Jan 2021, Double Blind Randomized Controlled Trial, Nigeria, peer-reviewed, baseline oxygen required 8.3%, 10 authors, study period May 2020 - November 2020, dosage 12mg or 6mg q84h for two weeks, this trial compares with another treatment - results may be better when compared to placebo.
This PaperIvermectinAll
Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos
Prof O E Babalola, C O Bode, A A Ajayi, F M Alakaloko, I E Akase, E Otrofanowei, O B Salu, W L Adeyemo, A O Ademuyiwa, S Omilabu
QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035
Introduction: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS-CoV-2 viral replication, but questions remained as to in-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods: We conducted a translational proof of concept randomized, double blind placebo controlled, dose response and parallel group study of IV efficacy in RT-polymerase chain reaction proven COVID 19 positive patients. Sixty-two patients were randomized to three treatment groups. (A) IV 6 mg regime, (B) IV 12 mg regime (given Q84 h for 2 weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care. Results: The Days to COVID negativity (DTN) was significantly and dose dependently reduced by IV (P ¼ 0.0066). The DTN for Control were, ¼ 9.1þ/-5.2, for A 6.0 þ/-2.9 and for B 4.6 þ/-3.2. Two way repeated measures ANOVA of ranked COVID 19 þ/scores at 0, 84, 168 and252h showed a significant IV treatment effect (P ¼ 0.035) and time effect (P < 0.0001). IV also tended to increase SPO2% compared to controls, P ¼ 0.073, 95% CI-0.39 to 2.59 and increased platelet count compared to C (P ¼ 0.037) 95%CI 5.55-162.55 Â 10 3 /ml. The platelet count increase was inversely correlated to DTN (r ¼ -0.52, P ¼ 0.005). No SAE was reported.
Conflict of interest. None declared.
References
Abiose, Jones, Murdoch, Cassels-Brown, Babalola et al., Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis, Lancet
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Anderson, Rouphael, Widge, Jackson, Roberts et al., Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults, N Engl J Med
Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritisation of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther
Babalola, None
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Carfı, Bernabei, Landi, For the Gemelli against COVID-19 post-acute care study group). Persistent symptoms in patients after acute COVID-19, JAMA
Cucinotta, Vanelli, WHO Declares COVID-19 a pandemic, Acta Bio Medica Atenei Parm
Dinicolantonio, Barroso, Mccarty, Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19, Open Heart
Dunn, Laboratory Diagnostics and Testing Guidance for COVID-19: Laboratory Studies, Specimen Selection, Collection, and Transport, Nucleic Acid Detection
Elfein, Number of Coronavirus (COVID-19) Cases, Recoveries and Deaths Worldwide as of February 8
Elgazzar, Hany, Youssef, Hafez, Moussa, Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Hussman, Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention, Front Pharmacol, doi:10.3389/fphar.2020.01169/full
Jackson, Weiss, Schwarzenberg, Nelson, Sutter et al., Global Economic Effects of COVID-19
Jans, Wagstaff, The broad-spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2?, Biochem Biophys Res Commun
Khullar, Bond, Schpero, COVID-19 and the financial health of US hospitals, JAMA
Liao, Zhou, Luo, Xu, Wang et al., Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study, Lancet Haematol
Luo, Li, Jiang, Wang, Ye, Signaling to control cytokine release syndrome in COVID-19, Trends Pharmacol Sci
Mojtabavi, Saghazadeh, Rezaei, Interleukin-6 and severe COVID-19: a systematic review and meta-analysis, Eur Cytokine Netw
Moore, June, Cytokine release syndrome in severe COVID-19, Science
Muñoz, Ballester, Antonijoan, Gich, Rodrı ´guez et al., Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg Tablet in healthy adult volunteers, PLoS Negl Trop Dis
Nandini, Sundararaj, Akihide, Interpreting diagnostic tests for SARS-CoV-2 Au, JAMA
Parvez, Karim, Hasan, Jaman, Karim et al., Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach
Polack, Thomas, Kitchin, Absalon, Gurtman et al., Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, N Engl J Med
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON Study, Chest
Schmith, Zhou, Lohmer, The approved dose of Ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther
Sjoding, Dickson, Iwashyna, Gay, Valley, Racial bias in pulse oximetry measurement, N Engl J Med
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin a/b1 heterodimer, Antiviral Res
Zhang, Song, Ci, Ju, Li, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T17:18:07Z', 'timestamp': 1712596687572}, 'reference-count': 30, 'publisher': 'Oxford University Press (OUP)', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2021, 2, 18]], 'date-time': '2021-02-18T00:00:00Z', 'timestamp': 1613606400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model'}], 'funder': [ { 'name': 'The Central Bank of Nigeria Health Sector Research and Development Intervention ' 'Scheme'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 1, 5]]}, 'abstract': '<jats:title>Summary</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Introduction</jats:title>\n' ' <jats:p>In vitro studies have shown the efficacy of Ivermectin (IV) to ' 'inhibit the SARS—CoV-2 viral replication, but questions remained as to in-vivo applications. ' 'We set out to explore the efficacy and safety of Ivermectin in persons infected with ' 'COVID19.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>We conducted a translational proof of concept randomized, double ' 'blind placebo controlled, dose response and parallel group study of IV efficacy in ' 'RT—polymerase chain reaction proven COVID 19 positive patients. Sixty-two patients were ' 'randomized to three treatment groups. (A) IV 6\u2009mg regime, (B) IV 12\u2009mg regime ' '(given Q84 h for 2\u2009weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of ' 'Care.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>The Days to COVID negativity (DTN) was significantly and dose ' 'dependently reduced by IV (P\u2009=\u20090.0066). The DTN for Control were, = 9.1+/–5.2, for ' 'A 6.0 +/– 2.9 and for B 4.6 +/–3.2. Two way repeated measures ANOVA of ranked COVID 19 +/– ' 'scores at 0, 84, 168 and252h showed a significant IV treatment effect (P\u2009=\u20090.035) ' 'and time effect (P\u2009&amp;lt;\u20090.0001). IV also tended to increase SPO2% compared to ' 'controls, P\u2009=\u20090.073, 95% CI—0.39 to 2.59 and increased platelet count compared to C ' '(P\u2009=\u20090.037) 95%CI 5.55—162.55\u2009×\u2009103/ml. The platelet count increase was ' 'inversely correlated to DTN (r = –0.52, P\u2009=\u20090.005). No SAE was reported.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>12mg IV regime given twice a week may have superior efficacy over ' '6mg IV given twice a week, and certainly over the non IV arm of the study. IV should be ' 'considered for use in clinical management of SARS-COV2, and may find applications in ' 'prophylaxis in high risk areas.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/qjmed/hcab035', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 15]], 'date-time': '2021-02-15T13:19:18Z', 'timestamp': 1613395158000}, 'page': '780-788', 'source': 'Crossref', 'is-referenced-by-count': 32, 'title': 'Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled ' 'double-blind, dose-response study in Lagos', 'prefix': '10.1093', 'volume': '114', 'author': [ { 'given': 'O E', 'family': 'Babalola', 'sequence': 'first', 'affiliation': [ { 'name': 'From the Department of Ophthalmology, Bingham University, ' 'Karu/Jos, Nassarawa/Plateau state, Nigeria'}]}, { 'given': 'C O', 'family': 'Bode', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Surgery, College of Medicine and Lagos University ' 'Teaching Hospital, Lagos, Nigeria'}]}, { 'given': 'A A', 'family': 'Ajayi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Hypertension and Clinical pharmacology, Keck ' 'Department of Medicine, Baylor College of Medicine Houston ' 'Texas, TX 77030, USA'}]}, { 'given': 'F M', 'family': 'Alakaloko', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Surgery, Lagos University Teaching Hospital, ' 'Lagos, Nigeria'}]}, { 'given': 'I E', 'family': 'Akase', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, Lagos University Teaching Hospital, ' 'Lagos, Nigeria'}]}, { 'given': 'E', 'family': 'Otrofanowei', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, Faculty of Clinical Sciences, College of ' 'Medicine/Lagos University Teaching Hospital, Lagos, Nigeria'}]}, { 'given': 'O B', 'family': 'Salu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Central Research Laboratory/Department of Medical Microbiology ' 'and Parasitology, Centre for Human and Zoonotic Virology, ' 'College of Medicine, University of Lagos, Lagos, Nigeria'}]}, { 'given': 'W L', 'family': 'Adeyemo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Oral and Maxillofacial Surgery, College of ' 'Medicine, University of Lagos, Lagos, Nigeria'}]}, { 'given': 'A O', 'family': 'Ademuyiwa', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Surgery, College of Medicine and Lagos University ' 'Teaching Hospital, Lagos, Nigeria'}]}, { 'given': 'S', 'family': 'Omilabu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Central Research Laboratory/Department of Medical Microbiology ' 'and Parasitology, Centre for Human and Zoonotic Virology, ' 'College of Medicine, University of Lagos, Lagos, Nigeria'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 2, 18]]}, 'reference': [ { 'key': '2022010715264238000_hcab035-B1', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '2022010715264238000_hcab035-B2', 'first-page': '157', 'article-title': 'WHO Declares COVID-19 a pandemic', 'volume': '91', 'author': 'Cucinotta', 'year': '2020', 'journal-title': 'Acta Bio Medica Atenei Parm'}, {'key': '2022010715264238000_hcab035-B3', 'author': 'Elfein', 'year': '2021'}, { 'key': '2022010715264238000_hcab035-B4', 'doi-asserted-by': 'crossref', 'first-page': '603', 'DOI': '10.1001/jama.2020.12603', 'article-title': 'Persistent symptoms in patients after acute COVID-19', 'volume': '324', 'author': 'Carfì', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '2022010715264238000_hcab035-B5', 'doi-asserted-by': 'crossref', 'first-page': '2127', 'DOI': '10.1001/jama.2020.6269', 'article-title': 'COVID-19 and the financial health of US hospitals', 'volume': '323', 'author': 'Khullar', 'year': '2020', 'journal-title': 'JAMA'}, {'key': '2022010715264238000_hcab035-B6', 'author': 'Jackson'}, { 'key': '2022010715264238000_hcab035-B7', 'doi-asserted-by': 'crossref', 'first-page': '2603', 'DOI': '10.1056/NEJMoa2034577', 'article-title': 'Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine', 'volume': '383', 'author': 'Polack', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2022010715264238000_hcab035-B8', 'doi-asserted-by': 'crossref', 'first-page': '2427', 'DOI': '10.1056/NEJMoa2028436', 'article-title': 'Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older ' 'adults', 'volume': '383', 'author': 'Anderson', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2022010715264238000_hcab035-B9', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}, {'key': '2022010715264238000_hcab035-B10', 'author': 'Jans', 'year': '2020'}, { 'key': '2022010715264238000_hcab035-B11', 'doi-asserted-by': 'crossref', 'first-page': '130', 'DOI': '10.1016/0140-6736(93)90002-X', 'article-title': 'Reduction in incidence of optic nerve disease with annual ivermectin to ' 'control onchocerciasis', 'volume': '341', 'author': 'Abiose', 'year': '1993', 'journal-title': 'Lancet'}, { 'key': '2022010715264238000_hcab035-B12', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, {'key': '2022010715264238000_hcab035-B13', 'author': 'Parvez', 'year': '2020'}, { 'key': '2022010715264238000_hcab035-B14', 'doi-asserted-by': 'crossref', 'first-page': '104760', 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'volume': '177', 'author': 'Yang', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '2022010715264238000_hcab035-B15', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1002/cpt.1889', 'article-title': 'The approved dose of Ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'volume': '108', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '2022010715264238000_hcab035-B16', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/cpt.1909', 'article-title': 'Prioritisation of anti-SARS-Cov-2 drug repurposing opportunities based ' 'on plasma and target site concentrations derived from their established ' 'human pharmacokinetics', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '2022010715264238000_hcab035-B17', 'doi-asserted-by': 'crossref', 'first-page': 'e0006020', 'DOI': '10.1371/journal.pntd.0006020', 'article-title': 'Safety and pharmacokinetic profile of fixed-dose ivermectin with an ' 'innovative 18mg Tablet in healthy adult volunteers', 'volume': '12', 'author': 'Muñoz', 'year': '2018', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '2022010715264238000_hcab035-B18', 'doi-asserted-by': 'crossref', 'first-page': '524', 'DOI': '10.1007/s00011-008-8007-8', 'article-title': 'Ivermectin inhibits LPS-induced production of inflammatory cytokines ' 'and improves LPS-induced survival in mice', 'volume': '57', 'author': 'Zhang', 'year': '2008', 'journal-title': 'Inflamm Res'}, { 'key': '2022010715264238000_hcab035-B19', 'article-title': 'Interpreting diagnostic tests for SARS-CoV-2 Au', 'author': 'Nandini', 'year': '2020', 'journal-title': 'JAMA'}, {'key': '2022010715264238000_hcab035-B20', 'author': 'Dunn'}, { 'key': '2022010715264238000_hcab035-B21', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'author': 'Ahmed', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, {'key': '2022010715264238000_hcab035-B22', 'author': 'Elgazzar', 'year': '2020'}, { 'key': '2022010715264238000_hcab035-B23', 'doi-asserted-by': 'crossref', 'first-page': '2477', 'DOI': '10.1056/NEJMc2029240', 'article-title': 'Racial bias in pulse oximetry measurement', 'volume': '383', 'author': 'Sjoding', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '2022010715264238000_hcab035-B24', 'doi-asserted-by': 'crossref', 'first-page': 'e671', 'DOI': '10.1016/S2352-3026(20)30217-9', 'article-title': 'Haematological characteristics and risk factors in the classification ' 'and prognosis evaluation of COVID-19: a retrospective cohort study', 'volume': '7', 'author': 'Liao', 'year': '2020', 'journal-title': 'Lancet Haematol'}, { 'key': '2022010715264238000_hcab035-B25', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1016/j.chest.2020.10.009', 'article-title': 'Use of Ivermectin is associated with lower mortality in hospitalized ' 'patients with coronavirus disease 2019: the ICON Study', 'volume': '159', 'author': 'Rajter', 'year': '2020', 'journal-title': 'Chest'}, { 'key': '2022010715264238000_hcab035-B26', 'doi-asserted-by': 'crossref', 'first-page': '473', 'DOI': '10.1126/science.abb8925', 'article-title': 'Cytokine release syndrome in severe COVID-19', 'volume': '368', 'author': 'Moore', 'year': '2020', 'journal-title': 'Science'}, { 'key': '2022010715264238000_hcab035-B27', 'doi-asserted-by': 'crossref', 'first-page': 'e001350', 'DOI': '10.1136/openhrt-2020-001350', 'article-title': 'Ivermectin may be a clinically useful anti-inflammatory agent for ' 'late-stage COVID-19', 'volume': '7', 'author': 'DiNicolantonio', 'year': '2020', 'journal-title': 'Open Heart'}, { 'key': '2022010715264238000_hcab035-B28', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fphar.2020.01169', 'article-title': 'Cellular and molecular pathways of COVID-19 and potential points of ' 'therapeutic intervention', 'volume': '11', 'author': 'Hussman', 'year': '2020', 'journal-title': 'Front Pharmacol'}, { 'key': '2022010715264238000_hcab035-B29', 'doi-asserted-by': 'crossref', 'first-page': '44', 'DOI': '10.1684/ecn.2020.0448', 'article-title': 'Interleukin-6 and severe COVID-19: a systematic review and ' 'meta-analysis', 'volume': '31', 'author': 'Mojtabavi', 'year': '2020', 'journal-title': 'Eur Cytokine Netw'}, { 'key': '2022010715264238000_hcab035-B30', 'doi-asserted-by': 'crossref', 'first-page': '531', 'DOI': '10.1016/j.tips.2020.06.007', 'article-title': 'Signaling to control cytokine release syndrome in COVID-19', 'volume': '41', 'author': 'Luo', 'year': '2020', 'journal-title': 'Trends Pharmacol Sci'}], 'container-title': 'QJM: An International Journal of Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/qjmed/advance-article-pdf/doi/10.1093/qjmed/hcab035/37968229/hcab035.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/qjmed/article-pdf/114/11/780/42079773/hcab035.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/qjmed/article-pdf/114/11/780/42079773/hcab035.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T15:27:44Z', 'timestamp': 1641569264000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/qjmed/article/114/11/780/6143037'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 18]]}, 'references-count': 30, 'journal-issue': { 'issue': '11', 'published-online': {'date-parts': [[2021, 2, 18]]}, 'published-print': {'date-parts': [[2022, 1, 5]]}}, 'URL': 'http://dx.doi.org/10.1093/qjmed/hcab035', 'relation': {}, 'ISSN': ['1460-2725', '1460-2393'], 'subject': ['General Medicine'], 'published-other': {'date-parts': [[2021, 11, 1]]}, 'published': {'date-parts': [[2021, 2, 18]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit